Showing 2011-2020 of 5909 results for "".
- Aviceda Announces Additional Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmologyhttps://modernod.com/news/aviceda-announces-additional-members-to-its-clinical-advisory-board-to-support-its-clinical-development-strategy-in-ophthalmology/2481232/Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators, announced the addition of ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are:
- Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officerhttps://modernod.com/news/atsena-therapeutics-expands-leadership-team-with-appointment-of-lis-leiderman-md-mba-as-chief-financial-officer-and-chief-business-officer/2481229/Atsena Therapeutics announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer. Dr. Leiderman has more than 15 years of finance, business development and strategy experience in the life sciences industry, most recently with gene the
- CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North Americahttps://modernod.com/news/coopervision-adds-synergeyes-to-expand-specialty-contact-lens-adoption-in-north-america/2481220/Deepening its commitment to expand specialty contact lens adoption in North America and worldwide, CooperVision has added
- Heru Makes Appointments to Its Executive Leadership Teamhttps://modernod.com/news/heru-makes-appointments-to-its-executive-leadership-team/2481210/Heru announced several key executive appointments across its leadership team and board of directors designed to strengthen the company’s commercial operation and support its next phase of growth. Fred Drasner has been appointed as Heru’s Chairman of the Board of
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on i
- Lenstec Rebrands its Newly Approved Multifocal IOL to ClearView 3https://modernod.com/news/lenstec-rebrands-its-newly-approved-multifocal-iol-to-clearview-3/2481174/Lenstec announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3 to better describe the vision patients can expect with the new IOL, according to Lenstec. The IOL was approved by the FDA in July 2022. "Since approval, the ClearView
- Atsena Therapeutics Announces Positive Results from Phase 1/2 Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1)https://modernod.com/news/atsena-therapeutics-announces-positive-results-from-phase-iii-clinical-trial-of-atsn-101-for-the-treatment-of-gucy2d-associated-leber-congenital-amaurosis-lca1/2481145/Atsena Therapeutics announced positive results from the phase 1/2 clinical trial of ATSN-101, its lead investigational gene therapy product formerly known as SAR439483, for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data demonstrated that su
- Ocuphire Expands Medical Advisory Board with Seven New KOLs; Expands Leadership Teamhttps://modernod.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/Ocuphire Pharma announced that it has appointed seven new key opinion leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, MS, has been promoted to Vice President, Business Development and Market St
- Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001https://modernod.com/news/frontera-therapeutics-receives-additional-ind-clearance-for-its-lead-program-ft-001/2481106/Frontera Therapeutics announced that its lead program, FT-001, a gene therapy product candidate targeting inherited retinal degenerations (IRDs) with a RPE65 mutation, successfully obtained an IND from the Center for Drug Evaluation (CDE), NMPA, in China. The FDA also cleared an IND for
- NIH Researchers Develop Gene Therapy for Rare Ciliopathyhttps://modernod.com/news/nih-researchers-develop-gene-therapy-for-rare-ciliopathy/2481074/Researchers from the National Eye Institute (NEI) have developed a gene therapy that rescues cilia defects in retinal cells affected by a type of Leber congenital amaurosis (LCA), a disease that causes blindness in early childhood. Using patient-derived retina organoids (also known as retinas-in-